180 related articles for article (PubMed ID: 34738211)
1. Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.
Ratra D; Roy K; Giridhar S; Madaan S;
Ophthalmol Ther; 2022 Feb; 11(1):135-149. PubMed ID: 34738211
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study.
Chakraborty D; Sengupta S; Mondal S; Boral S; Das A; Sinha TK; Bhattacharya R; Maitra R
Ophthalmol Ther; 2022 Apr; 11(2):629-638. PubMed ID: 35075621
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
4. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
6. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
7. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion.
Ozgonul C; Dedania VS; Besirli CG
J Ocul Pharmacol Ther; 2018 May; 34(4):340-345. PubMed ID: 29447089
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
[TBL] [Abstract][Full Text] [Related]
11. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
Niederhauser N; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
[TBL] [Abstract][Full Text] [Related]
12. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
Roller AB; Amaro MH
Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.
Yanagi Y; Takahashi K; Iida T; Gomi F; Morii J; Kunikane E; Sakamoto T
Ophthalmol Ther; 2023 Aug; 12(4):2005-2021. PubMed ID: 37171557
[TBL] [Abstract][Full Text] [Related]
17. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
Sepah YJ; Sadiq MA; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus D; Halperin L; Hassan M; Campochiaro PA; Nguyen QD; Do DV;
Ophthalmology; 2016 Dec; 123(12):2581-2587. PubMed ID: 27707550
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
20. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.
Kiss S; Liu Y; Brown J; Holekamp NM; Almony A; Campbell J; Kowalski JW
Clin Ophthalmol; 2014; 8():1611-21. PubMed ID: 25210429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
